GeoVax Calls for Manufacturing Expansion Before FIFA World Cup's 6.5M Attendees
GOVX•GeoVax highlights public health readiness for FIFA World Cup 2026, projecting 6.5M attendees and over 1.2M international visitors to U.S., stressing need to expand vaccine manufacturing, diversify supply chains and enhance surveillance. The company’s GEO-MVA poxvirus vaccine candidate targets mpox/smallpox, with Phase 3 trial planned H2 2026.
1. World Cup Operational Challenge
FIFA World Cup 2026 is expected to draw approximately 6.5 million attendees across the U.S., Canada and Mexico, including over 1.2 million international visitors to U.S. host cities. GeoVax underscores that mass gatherings of this scale will test disease surveillance, healthcare surge capacity, public communication networks and cross-jurisdiction coordination.
2. Biodefense Priorities for 2026
GeoVax identifies key priorities ahead of the tournament: expanding domestic vaccine manufacturing capacity, diversifying critical medical countermeasure supply chains, enhancing disease surveillance and rapid-response capabilities, and improving stockpile management and deployment logistics to address simultaneous biological threats.
3. GeoVax Vaccine Pipeline
The company’s lead program, GEO-MVA, is an MVA-based poxvirus vaccine targeting mpox and smallpox, with a pivotal Phase 3 clinical trial slated for the second half of 2026. GeoVax also advances immuno-oncology candidate Gedeptin and preclinical vaccines for hemorrhagic fever pathogens such as Ebola and Marburg.
